Skip Navigation LinksHome > June 19, 2009 - Volume 23 - Issue 10 > The safety of candidate vaginal microbicides since nonoxynol...
doi: 10.1097/QAD.0b013e32832b4271
Clinical Science

The safety of candidate vaginal microbicides since nonoxynol-9: a systematic review of published studies

Poynten, I Marya; Millwood, Iona Ya; Falster, Michael Oa; Law, Matthew Ga; Andresen, David Nb; Van Damme, Lutc; Kaldor, John Ma

Collapse Box


Objective: To gain a greater understanding of published safety data for candidate vaginal microbicides.

Design: A systematic review of human safety trials of candidate vaginal microbicides – agents designed to protect women against HIV and other sexually transmitted infections.

Methods: Trials were published in peer-reviewed journals, and publication cut-off was August week 4, 2008. Trials of nonoxynol-9 were excluded, as were trials without a control group, trials that enrolled only male participants or reported on the investigation of a product for the treatment of a genital infection.

Results: Twenty-one trials of 11 products, involving 1465 women, satisfied review criteria. Most trials reported on genital epithelial findings and urogenital symptoms and a number reported a range of other local and systemic toxicity endpoints. Trials were generally of short duration (2 weeks or less) with small sample sizes. There were few findings of significant difference between women in active and control arms. Among the products assessed in more than one study, there were significantly more genital findings with intact epithelium in recipients of PRO2000 [relative risk (RR) 1.68, 95% confidence interval (CI) 1.08–2.60] and a lower incidence of bacterial vaginosis in dextrin sulphate recipients (RR 0.61, 95% CI 0.42–0.88). CIs were generally very wide, and most studies were unable to exclude differences of a substantial magnitude between treated and control women.

Conclusion: Larger and longer safety studies are necessary to detect clinically important toxicities, including those that indicate a potential increase in HIV risk, and provide assurance that agents are ready for large-scale effectiveness trials.

© 2009 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.